tyrosine kinase inhibitors
MARS: mutation-adjusted risk score for advanced systemic mastocytosis
Andreas Reiter • 15 Nov 2019
CML-IT-MOS: clinical characteristics of CML patients not included in clinical trials
Predictors for TFR in CML: response duration, secondary treatment & frontline TKI choice
Timothy Hughes • 12 Sep 2018
Resistance/intolerance to second generation TKIs in CML: what to do next?
Giuseppe Saglio • 12 Sep 2018